SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...

Obesity treatment shifts from surgery to drugs as bariatric procedures decline by 25.6% and GLP-1 receptor agonist use jumps ...

25, 2024 — A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity ...

Semaglutide compounders could be next: Novo Nordisk has asked the FDA to bar compounding pharmacies from making compounds of ...

The use of weight loss drugs without doctor's supervision is not advisable and can lead to serious side effects and ...

A daily anti-smoking pill will be made available to almost 100,000 patients a year on the ... As well as stricter rules on ...

A groundbreaking study shows that the weight-loss drug semaglutide can significantly reduce knee pain from obesity-related ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...